Fluigent Holding 1A

Equity
Smart Microfluidics
€1,758,500
total amount raised
This campaign has been closed

Market positioning


The company’s positioning is high-end and perceived as such by its clients thanks to innovative and highly performing products and an optimal after-sales service (training, phone line, software updates, etc). Clients, usually scientists who write scientific publications, play an essential commercial role. They are Key Opinion Leaders.
As long as they have appropriate budget (coming from public institutions), researchers favour high quality materials saving time and materials.

Market trends


The global microfluidics market is projected to reach $ 8.78 Billion by 2021, at a CAGR of 19.2% from 2016 to 2021. This market is mainly driven by the rising demand for point-of-care (POC) testing, increasing demand for microfluidic chip miniaturization as it offers lower testing time and improved portability, growing Asian market, rising incidences of lifestyle diseases, increasing R&D expenditure and healthcare spending, and growing stem cell and cancer research.

However, strict regulatory framework, high excise duty on these products, high prices of microfluidics-based genomic and proteomic analysis platforms and lack of proper healthcare and research infrastructure in emerging markets are restraining the growth of the global market to a certain extent.

In 2015, the in vitro diagnostics segment (Industrial and Environment Testing, Point of Care, Analytical Device and Clinical & Veterinary Diagnostics) and the Pharmaceutical and Life Science Research represents the largest shares of the market.